Observational studyResearch and practice in thrombosis and haemostasis2026
Postbleeding antithrombotic management in cardiovascular patients: insights from the Attica Bleeding Snapshot study.
Observational study in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bleeding complications in cardiovascular patients receiving antithrombotic therapy pose a major clinical challenge, particularly given the limited evidence guiding antithrombotic management after a bleeding event. Objectives: This snapshot study aimed to evaluate the burden of major bleeding events requiring hospitalization and to describe real-world practices in postbleeding antithrombotic management. Methods: The Attica Bleeding Snapshot was a multicenter, cross-sectional observational study conducted from February 17 to 21, 2025, in the Internal Medicine and Gastroenterology Departments of 17 hospitals in the Attica region, Greece. Adult patients hospitalized for major bleeding while receiving antithrombotic therapy for cardiovascular indications were included. Data collected comprised demographics, comorbidities, antithrombotic regimens, bleeding site, management strategies, and in-hospital outcomes. Results: Of 1540 hospitalized patients, 134 (8.7%) experienced major bleeding while on antithrombotic therapy. The mean ± SD age was 79.5 ± 11.1 years, and 38.1% were female. Atrial fibrillation was the most frequent indication for antithrombotic therapy (46.2%), followed by coronary artery disease (20.9%). Gastrointestinal bleeding accounted for 63.5% of cases. In-hospital mortality was 14.9%, with frailty independently associated with mortality (odds ratio, 1.64; 95% CI, 1.24-2.16; Conclusion: Major bleeding during antithrombotic treatment is associated with substantial morbidity and mortality in cardiovascular patients. Postbleeding antithrombotic management remains highly heterogeneous, underscoring a critical unmet need. Alternative strategies for thromboembolic prevention, including left atrial appendage occlusion, merit consideration in selected high-risk atrial fibrillation patients, particularly those with recurrent bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.